Trial results for a study investigating cellular kinases and aging in patients with HIV were posted on ClinicalTrials.gov on 2025-12-24, detailing various median concentrations in 21 enrolled participants.
Background
HIV infection and the aging process can both impact cellular function and metabolic pathways. Understanding how these factors, along with specific antiretroviral medications like tenofovir and emtricitabine, influence key enzymes in different tissues is important for comprehensive patient care. This study aimed to explore the effect of aging on certain enzymes, or proteins, in the blood and colon, and to investigate how tenofovir and emtricitabine interact with these enzymes.
Trial design
This completed study enrolled 21 participants with conditions including HIV Infections and Aging. The study's goal was to learn about the effect of aging on specific enzymes in peripheral blood mononuclear cells (PBMCs) and colorectal tissue. It also investigated the interaction of tenofovir and emtricitabine with these enzymes, comparing enzyme activity between people taking these medications and those who were not.
Key results
The trial results provide median concentration values for AK2 and CKM in colorectal tissue and AK2 in peripheral blood mononuclear cells across different participant groups. Dispersion values (Inter-Quartile Range) were not provided for these measurements.
- Concentration of AK2 in Colorectal Tissue:
- For HIV Negative participants not taking Tenofovir (TFV) Based PrEP (18-50 Years), the median concentration was 12232 nm.
- For HIV Negative participants not taking Tenofovir (TFV) Based PrEP (65-80 Years), the median concentration was 12975 nm.
- For HIV Positive participants taking Tenofovir (TFV) and Emtricitabine (FTC) Based HIV Treatment (65-80 Yrs), the median concentration was 13173 nm.
- Concentration of CKM in Colorectal Tissue:
- For HIV Negative participants not taking Tenofovir (TFV) Based PrEP (18-50 Years), the median concentration was 4143 nm.
- For HIV Negative participants not taking Tenofovir (TFV) Based PrEP (65-80 Years), the median concentration was 3236 nm.
- For HIV Positive participants taking Tenofovir (TFV) and Emtricitabine (FTC) Based HIV Treatment (65-80Yrs), the median concentration was 4176 nm.
- Concentration of AK2 in Peripheral Blood Mononuclear Cells:
- For HIV Negative participants not taking Tenofovir (TFV) Based PrEP (18-50 Years), the median concentration was 2035 nm.
- For HIV Negative participants not taking Tenofovir (TFV) Based PrEP (65-80 Years), the median concentration was 1175 nm.
- For HIV Positive participants taking Tenofovir (TFV) and Emtricitabine (FTC) Based HIV Treatment (65-80 Yrs), the median concentration was 1740 nm.
What this means
The posted results provide specific median concentration data for AK2 and CKM in colorectal tissue and AK2 in peripheral blood mononuclear cells. This descriptive data offers insights into the levels of these cellular kinases in different populations, including younger and older HIV-negative individuals, and older HIV-positive individuals on tenofovir and emtricitabine. These measurements contribute to the understanding of how aging and HIV treatment may influence enzyme activity in relevant tissues and cells.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06132386, titled "Analysis of Cellular Kinases and Aging in PBMCs and Colorectal Tissue", were posted on 2025-12-24 on clinicaltrials.gov.